334 related articles for article (PubMed ID: 25523883)
1. Curcumin and major depression: a randomised, double-blind, placebo-controlled trial investigating the potential of peripheral biomarkers to predict treatment response and antidepressant mechanisms of change.
Lopresti AL; Maes M; Meddens MJ; Maker GL; Arnoldussen E; Drummond PD
Eur Neuropsychopharmacol; 2015 Jan; 25(1):38-50. PubMed ID: 25523883
[TBL] [Abstract][Full Text] [Related]
2. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study.
Lopresti AL; Maes M; Maker GL; Hood SD; Drummond PD
J Affect Disord; 2014; 167():368-75. PubMed ID: 25046624
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study.
Lopresti AL; Drummond PD
J Affect Disord; 2017 Jan; 207():188-196. PubMed ID: 27723543
[TBL] [Abstract][Full Text] [Related]
4. Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Yu JJ; Pei LB; Zhang Y; Wen ZY; Yang JL
J Clin Psychopharmacol; 2015 Aug; 35(4):406-10. PubMed ID: 26066335
[TBL] [Abstract][Full Text] [Related]
5. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
[TBL] [Abstract][Full Text] [Related]
6. Add-on Treatment with Curcumin Has Antidepressive Effects in Thai Patients with Major Depression: Results of a Randomized Double-Blind Placebo-Controlled Study.
Kanchanatawan B; Tangwongchai S; Sughondhabhirom A; Suppapitiporn S; Hemrunrojn S; Carvalho AF; Maes M
Neurotox Res; 2018 Apr; 33(3):621-633. PubMed ID: 29327213
[TBL] [Abstract][Full Text] [Related]
7. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
8. Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study.
Bergman J; Miodownik C; Bersudsky Y; Sokolik S; Lerner PP; Kreinin A; Polakiewicz J; Lerner V
Clin Neuropharmacol; 2013; 36(3):73-7. PubMed ID: 23673908
[TBL] [Abstract][Full Text] [Related]
9. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
10. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.
Inamdar A; Merlo-Pich E; Gee M; Makumi C; Mistry P; Robertson J; Steinberg E; Zamuner S; Learned S; Alexander R; Ratti E
J Psychopharmacol; 2014 Jun; 28(6):570-81. PubMed ID: 24699061
[TBL] [Abstract][Full Text] [Related]
12. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
13. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
14. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled trial of pioglitazone for bipolar depression.
Aftab A; Kemp DE; Ganocy SJ; Schinagle M; Conroy C; Brownrigg B; D'Arcangelo N; Goto T; Woods N; Serrano MB; Han H; Calabrese JR; Gao K
J Affect Disord; 2019 Feb; 245():957-964. PubMed ID: 30699881
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
Brown ES; Howard C; Khan DA; Carmody TJ
Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]